Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 74.9% in September

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 205,900 shares, a decline of 74.9% from the September 15th total of 818,700 shares. Based on an average daily trading volume, of 539,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.4% of the shares of the company are short sold.

Aptose Biosciences Stock Performance

Shares of NASDAQ:APTO remained flat at $0.37 during trading on Friday. The stock had a trading volume of 57,236 shares, compared to its average volume of 229,026. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.32. The company has a market capitalization of $7.38 million, a P/E ratio of -0.08 and a beta of 1.26. The company has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.82.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.15.

Wall Street Analysts Forecast Growth

APTO has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June 14th. StockNews.com assumed coverage on Aptose Biosciences in a research note on Saturday. They set a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Aptose Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.